Peptide Database

Browse and search our comprehensive peptide database. Click any peptide for detailed information including protocols, benefits, and side effects.

All Healing Weight Loss Cognitive function Longevity Immune system Muscles Skin Sleep Mitochondrial Mood Energy Bones Focus Pain

5-amino-1MQ

Unknown
Muscles Weight Loss Immune system

Key benefits:
• Assists with weight loss
• Helps with muscle preservation

AOD-9604

4.00 minutes
Weight Loss Healing

Modified form of Frag 176-191. AOD stands for Anti Obesity Drug.

Key benefits:
• Used for weight loss
• Believed to help reduce body fat and prevent new fat growth

Cagrilintide

168.00 hours
Weight Loss

Long-acting amylin analog by Novo Nordisk. Activates amylin receptors (separate from GLP-1 pathway) to reduce appetite, slow gastric emptying, and promote satiety. Combined with semaglutide as "CagriSemia" (brand name: Ystegrity). Weekly subcutaneous injection.

Key benefits:
• Activates amylin receptors — a completely separate satiety pathway from GLP-1 agonists
• Slows gastric emptying and reduces food intake

Frag 176-191

Unknown
Weight Loss Bones Sleep

HGH Fragment 176-191 peptide is a modified form of amino acids 176-191 of the human Growth Hormone.

Key benefits:
• Induces fat breakdown
• Prevents new fat growth

Ipamorelin

2.00 hours
Sleep Muscles Weight Loss Immune system

Human growth hormone releasing peptide (GHRP).

Key benefits:
• Increased cellular repair and regeneration
• Collagen production

MOTS-C

Unknown
Mitochondrial Energy Weight Loss Longevity

Key benefits:
• Significantly decreases fat accumulation in the liver
• Improves cardiovascular health

NAD+

Unknown
Longevity Immune system Cognitive function Weight Loss

Nicotinamide Adenine Dinucleotide.

Key benefits:
• Produces anti-aging benefits
• Increases energy levels

Retatrutide

144.00 hours
Weight Loss Longevity Mitochondrial

Triple hormone receptor agonist (GLP-1 / GIP / glucagon) by Eli Lilly. Code name LY3437943. Phase 3 as of 2024. Not yet FDA approved — available only through clinical trials.

Key benefits:
• Triple action: stimulates GLP-1 and GIP receptors (satiety, insulin sensitization) plus glucagon receptors (increased energy expenditure, hepatic fat clearance)
• Up to 22.8-24.2% body weight loss at 48 weeks in Phase 2 (8-12 mg doses)

Semaglutide

165.00 hours
Weight Loss Longevity Mitochondrial

FDA-approved GLP-1 receptor agonist. Marketed as Ozempic (type 2 diabetes) and Wegovy/Wegovy HD (chronic weight management). Weekly subcutaneous injection.

Key benefits:
• Activates GLP-1 receptors to increase satiety and reduce hunger
• Clinically proven ~15% average weight loss on Wegovy (2.4 mg weekly) over 68 weeks

Sermorelin

6.00 minutes
Longevity Weight Loss Muscles Cognitive function

Also known as GRF 1-29 ("Old" CJC-1295).

Key benefits:
• Reduced body fat
• Increased energy and vitality

Tesamorelin

30.00 minutes
Weight Loss Bones Muscles Focus

Brand name - EGRIFTA. Developed to treat HIV lipodystrophy. Human growth hormone-releasing hormone (GHRH).

Key benefits:
• Reduce triglycerides, liver and visceral fat
• Decrease middle fat

Tesofensine

Unknown
Focus Weight Loss Energy

Key benefits:
• Appetite suppressant
• Decreases triglycerides

Tirzepatide

120.00 hours
Weight Loss Longevity Mitochondrial

Dual GIP/GLP-1 receptor agonist. Marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Weekly subcutaneous injection by Eli Lilly.

Key benefits:
• Dual action on GIP and GLP-1 receptors — stronger appetite suppression and satiety signaling than GLP-1 alone
• Average 15-22.5% body weight loss over 72 weeks at highest dose (Zepbound)